Key Events This Week
15 Jun: New 52-week high at Rs.2,445
16 Jun: Golden Cross formation signalling bullish breakout
17 Jun: Upgrade to Buy rating on strong technical and financials
19 Jun: New 52-week high at Rs.2,462 and intraday surge of 7.94%
Jun 25, 03:30 PM
BSE+NSE Vol: 81.42 k

Caplin Point Laboratories Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This transition is underscored by a combination of technical indicators including MACD, RSI, moving averages, and Bollinger Bands, signalling renewed investor interest and potential upside in the Pharmaceuticals & Biotechnology sector.
Read full news article
Caplin Point Laboratories Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 22 June 2026. This revision reflects a nuanced assessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals. While the company continues to demonstrate strong financial performance and management efficiency, evolving technical indicators and valuation metrics have prompted a more cautious stance.
Read full news article
Caplin Point Laboratories Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in price momentum and technical indicators, prompting an upgrade in its Mojo Grade from Hold to Buy as of 16 June 2026. The stock’s recent surge, reflected in a 6.22% day change and a closing price near its 52-week high, signals renewed investor interest despite some mixed signals from key technical metrics.
Read full news article
15 Jun: New 52-week high at Rs.2,445
16 Jun: Golden Cross formation signalling bullish breakout
17 Jun: Upgrade to Buy rating on strong technical and financials
19 Jun: New 52-week high at Rs.2,462 and intraday surge of 7.94%

The Sensex declined by 0.68% on 19 Jun 2026, while Caplin Point Laboratories Ltd surged 7.94%, touching an intraday high of Rs 2529. This 6.57-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector highlights a distinctly stock-specific rally rather than a broad market lift.
Read full news article
With every major moving average breached and a strong confluence of technical indicators, Caplin Point Laboratories Ltd surged to a fresh 52-week high of Rs 2462 on 19 Jun 2026, marking a significant milestone in its price momentum.
Read full news article
Caplin Point Laboratories Ltd has been upgraded from a Hold to a Buy rating, reflecting significant improvements across technical indicators, financial trends, valuation metrics, and overall quality. This upgrade, effective from 16 June 2026, is underpinned by robust quarterly results, a bullish technical outlook, and consistent long-term returns that have outpaced benchmark indices.
Read full news article
Caplin Point Laboratories Ltd has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a bullish stance. This change is underscored by a combination of moving averages, MACD, and Bollinger Bands signals, suggesting renewed investor confidence in the pharmaceuticals and biotechnology sector stock.
Read full news articleCaplin Point Laboratories Limited has informed the Exchange regarding a press release dated December 03, 2019, titled "CAPLIN STERILES GETS USFDA APPROVAL FOR SODIUM NITROPRUSSIDE INJECTION".
Caplin Point Laboratories Limited has informed the Exchange regarding 'Notice of Postal Ballot'.
Caplin Point Laboratories Limited has informed the Exchange regarding Reappointment of Director of the company.
No Upcoming Board Meetings
Caplin Point Laboratories Ltd has declared 200% dividend, ex-date: 29 May 26
Caplin Point Laboratories Ltd has announced 2:10 stock split, ex-date: 19 Oct 16
No Bonus history available
No Rights history available